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Malignant gliomas are the most common neoplasm in the central nervous system. When treated with conventional treatments
includingsurgery,irradiation,andchemotherapy,theaveragelifeexpectancyofthemostmalignanttype,glioblastomamultiformeis
usuallylessthan1year.Therefore,genetherapyisexpectedtobeaneﬀectiveandpossiblycurativetreatment.Manygenetherapeutic
approaches have demonstrated eﬃcacy in experimental animal models. However, the current clinical trials are disappointing. This
review focuses on current therapeutic genes/vectors/delivery systems/targeting strategies in order to introduce updated trends and
hopefully indicate prospective gene therapy for malignant gliomas.
INTRODUCTION
Malignant gliomas are the most common primary tu-
mors arising in the human brain [1]. The most malignant
type of them, the glioblastoma multiforme, represents
29% of all primary brain tumors or 5,000 new cases per
year in the United States [2]. Despite surgery, chemother-
apy, and radiotherapy, glioblastomas are almost alwaysfa-
tal, with a median survival rate of less than a year and a
5-year survival rate of 5% or less [1, 2, 3]. No therapeu-
tic modality has substantially changed the outcome of pa-
tients with glioblastoma [2, 3]. Therefore, it is no wonder
that one of the earliest targets of cancer gene therapy was
malignant glioma.
The epoch-making human trial of herpes simplex
virus thymidine kinase gene/ganciclovir (HSV-tk/GCV)
usingretroviralvectorstartedinearly1990s[4].Although
the antitumor eﬀect of HSV-tk/GCV therapy had looked
very promising in the animal model, the eﬀect on human
patients was disappointing. To augment the eﬀect of gene
therapy, adenoviral vectors were developed and advanced
to human trials [5]. Adenoviral vectors signiﬁcantly im-
proved transduction eﬃcacy but raised other problems,
as discussed later in this review. Additionally, there was
a death of a patient who received gene therapy using
an adenoviral vector [6]. This incident raised a nation-
wide debate especially on the safety of gene therapy us-
ing viral vectors. Most of clinical trials were put on hold
for several months to make sure that safety guidelines
are strictly followed. However, hopes for gene therapy
have not been quenched out. Researchers have been ex-
ploring many candidate genes, developing improved viral
and nonviral vectors, trying diﬀerent methods to deliver
genes, and combining gene therapies with other modali-
ties such as immunotherapy. In this review, we focus on
animal and human studies of gene therapy for malignant
gliomas. We have collected relatively recent references to
introduce updated trends and hopefully to indicate future
directions in this ﬁeld.
THERAPEUTIC GENES
Many therapeutic genes have shown eﬃcacy in exper-
imental models and been divided into three categories.
First, therapeutic genes are used to induce direct killing
eﬀect (Table 1). In this category, HSV-tk/GCV [5, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16], toxin [17], tumor suppres-
sor genes [18, 19, 20, 21, 22, 23, 24, 25, 26], apoptosis-
inducers [27, 28, 29, 30, 31, 32], antisense against telom-
erase [25,33,34,35], and oncolytic viruses [36,37,38,39,
40] are included. Second, immunomodulation has been
performed to elicit immune response against malignant
gliomas [41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53,
54].Third,angiogenesisinhibitors [55,56,57,58]o rne u-
ral stem cells [59, 60, 61] are used to induce antitumor
eﬀect, although direct killing eﬀect or direct immunore-
action may be unrelated.
Directkillingeffect
HSV-tk/GCV
Herpes simplex virus thymidine kinase gene/
ganciclovir (HSV-tk/GCV) therapy is a two-step strategy
[4]. First, HSV-tk gene is transduced into tumor cells.
Second, GCV is administered systematically. GCV is
harmless to normal cells without HSV-tk.W h e nt u m o r26 Takao Kanzawa et al 2003:1 (2003)
Table 1. Therapeutic genes.
Direct killing eﬀect References
HSV-tk/GCV
[5, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16]
Toxin [17]
Tumor suppresor gene [18, 19, 20, 21, 22, 23, 24,
25, 26]
Apoptosis inducer [27, 28, 29, 30, 31, 32]
Antisense therapy for telomerase [25, 33, 34, 35]
Oncolytic virus [36, 37, 38, 39, 40]
Immunomodulation References
IL-2 [41, 42, 43]
IL-4 [44, 45, 46]
IL-12 [47, 48]
IFN [49, 50]
TNF-α [51, 52, 53, 54]
Others References
Angiogenesis inhibitor [55, 56, 57, 58]
Neural stem cell [59, 60, 61]
cells express HSV-tk, this enzyme converts GCV into a
cytotoxic molecule, resulting in cell death. This HSV-
tk/GCV therapy is also called suicide gene therapy.
When HSV-tk gene is transduced with retroviral vectors,
these vectors are selectively incorporated into dividing
cells, predominantly into brain tumor cells. However,
the original scheme using retroviral vectors turned out
to be not potent enough. In vivo studies showed that
eﬀective tumor-cell killing depends on bystander eﬀect
and transduction eﬃcacy [7, 13]. Bystander eﬀect refers
to killing cells that do not express HSV-tk,b u tc l o s e l y
located with the cells expressing the enzyme. On the other
hand, to improve transduction eﬃcacy, retroviral-vector
producing cells or adenoviral vectors were developed.
Many human trials of HSV-tk/GCV therapy were carried
out using either retroviral-vector producing cells or
adenoviral vectors. Some phase I/II studies reported
signiﬁcant therapeutic responses in small groups of pa-
tients [10, 14], but others claimed only marginal beneﬁt
[5, 11, 15]; overall, results were disappointing. The main
reasons of failure are assumed to be low transduction
eﬃcacy and lack of bystander eﬀect. Additionally, there
was a report warning that adenoviral vector induced
long-term active inﬂammation in the animal model [12].
More recently, HSV-tk/GCV therapy is used in in vivo
experiments with adeno-associated virus [9] or combined
with other therapy [16].
Toxin
Martinetalconstructedretroviralvectorswithatoxin
gene (the Pseudomonas exotoxin or the Ricinus toxin,
ricin) placed under the control of the thyroid hormone
(T3) regulatable promoter of the myelin basic protein
(MBP) [17]. They showed that malignant glioma cells,
stably transducted with the vector, failed to establish a tu-
mor or regressed the tumor mass in the rat brain.
Tumorsuppressorgenes
T u m o rs u p p r e s s o rg e n e sa r eo f t e nm u t a t e do rd e l e t e d
in malignant gliomas and the lack of function of these
genes is supposed to cause tumorigenicity. Therefore, it
is quite reasonable to replace them. The most extensively
studied is the p53 tumor suppressor gene. Since alter-
ations in the p53 gene occur in 35–60% of human ma-
lignant glioma [62, 63], p53 gene therapy is logically
appropriate for these tumors. Accumulating evidences
show that replacement of p53 signiﬁcantly inhibits tu-
mor growth in the subcutaneous [19] or intracranial
[18, 22, 24] tumor model. However, many gliomas are
mixture of cells with mutated p53 and wild-type p53 (wt-
p53), and p53 gene transfer is known to be ineﬀective for
the cells with wt-p53 [23, 25]. That is, p53 gene ther-
apy is supposed to be eﬀective only for part of malig-
nant gliomas. There is a conﬂicting report claiming that
p53 gene therapy induces apoptosis in glioma cells with
wt-p53 [24]. New studies show that the combination of
p53 gene therapy and irradiation is eﬀective for malig-
nantgliomaswithheterogenousp53status[20,21].Other
tumor suppressor genes (p21, p16, and p27) belong to
cyclin-dependent kinase inhibitors (CDKIs) and they are
involved in the regulation of cell cycle. Wang et al showed
that retroviral transfer of p16 and p21 inhibited tumor
growth [26].
Apoptosis-inducers
Apoptosis, also called programmed cell death, is a
genetically-encoded program to get rid of unwanted cells.
It is well known that apoptotic pathways are suppressed
in malignancies including malignant gliomas [64]. The
rationale to use apoptosis-inducers is to activate apop-
totic pathways and induce cell death eﬀectively in malig-
nant glioma cells. The genes used in the studies so far are
caspase-1/interleukin-1β-converting enzyme (ICE) [27],
caspase-3/CPP32β [28], caspase-6 [32], caspase-8 [30],
Fas associated protein with death domain (FADD) [29],
and Bax [31]. The main concern of these strategies is
about safety, what if apoptosis is also induced in normal
brain cells surrounding the tumor? It is necessary to regu-
late the induction of apoptosis to occur only in malignant
c e l l sa sd e s c r i b e db e l o w .
Antisensetherapyfortelomerase
Our group developed a system to inhibit human
telomerase RNA (hTER) with 2-5A-linked antisense [25,
33, 35]. 2-5A or 2
 ,5
 -oligoadenylate is a pathway of inter-
feron actions [65, 66]. It activates RNase L that is ubiqui-
tous in the cells and degrades RNA randomly. Chimeric
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degrade speciﬁc RNA [67]. We designed an antisense and
synthesized 2-5A antisense molecule to target hTER (2-
5A-anti-hTER) [33]. It degrades hTER speciﬁcally and
eﬀectively, resulting in the inhibition of telomerase. In-
terestingly, 2-5A-anti-hTER induced apoptosis massively
and inhibited tumor growth in the subcutaneous and in-
tracranial tumor models [33, 35]. 2-5A-anti-hTER in-
duced apoptosis unexpectedly early (within 4 days, in
vitro) compared to the treatment with the cDNA vector
for hTER (about one month) [34].
Oncolyticviruses
Oncolytic viruses are designed to replicate selectively
i na n dl y s et u m o rc e l l s .T h e s ev i r u s e sa r em o r ee ﬀective
in infecting tumor cells compared to the viruses that are
constructed as replication-defective. Oncolytic viruses in-
crease in number in tumor cells and lyse the cells directly,
not by transducing speciﬁc genes. A recombinant her-
pes simplex virus with some deletions, designated DM33,
inhibited growth of intracranial tumors and prolonged
the survival of tumor-bearing animals [38]. The tumor-
killing eﬀect was even better with the following injec-
tion of ganciclovir [40]. Adenovirus ONYX-015 targets
tumors with mutant p53 and its clinical studies are ongo-
ing for head and neck cancer. Recently, it was shown that
ONYX-015 is eﬀective in malignant gliomas regardless of
their p53 status [39]. Fueyo et al constructed Delta 24, a
tumor-selective adenovirus with a deletion in the EIA re-
gion responsible for binding Rb protein [36]. This virus
targets tumor cells with Rb alteration. They showed that
Delta 24 inhibited the growth of glioma cells implanted
subcutaneously. Ansardi et al constructed oncolytic RNA-
based vectors derived from poliovirus and termed repli-
cons [37]. They showed that replicons suppressed tumor
growth and extended the survival of the animals with in-
tracranial tumors.
Immunomodulation
Central nervous system (CNS) had been considered
as immune-privileged site. The important factors of tol-
erance for activated host immune are the presence of
the blood-brain barrier and the absence of a lymphatic
drainage system [68]. However, lymphocytic inﬁltration
has been observed frequently in malignant gliomas and
the degree of inﬁltration seems to correlate with sur-
vival [69]. Moreover, disability to elicit the immune reac-
tion implies that the oncogenesis of primary glioma cells
occurs without interaction to immune cells. Therefore,
glioma cells derived from brain parenchyma may be more
immunogenic than tumors derived from peripheral sys-
tem and the immunogene therapy is very attractive for
therapy of malignant glioma.
IL-2
Interleukin (IL)-2, a cytokine produced by activated T
cells, can promote immune reactions. Fibroblasts, genet-
ically engineered to secrete IL-2, suppress tumor growth
and induce antitumor immunity to murine gliomas in
vivo [41]. Clinically, patients with malignant glioma were
subcutaneously immunized with autologous glioma cells
andr ec ei v edIL -2secr etingﬁbr oblasts[42].Posttreatment
withMRIrevealedthemarkedtumornecrosis,butthetu-
mor did not disappear. As shown in vivo immunother-
apy model using IL-2, the combination of immunization
in peripheral tissues and intracerebral transplantation of
IL-2-producing cells is necessary to eliminate established
brain tumors [43].
IL-4
IL-4 is a multifunctional lymphokine produced by
helper T cells and has a broad range of activities on
bothBandTlymphocytes.WhenIL-4-transducedglioma
cells were injected into animals, eosinophil inﬁltration
and inhibition of tumor angiogenesis were observed in
athymic mice [45] and T-cell inﬁltration and humoral re-
sponse were shown in immunocompetent rats [46]. Fur-
thermore, retroviral packaging cells producing IL-4 were
produced [44]. When these cells were injected into estab-
lished intracranial tumors, tumors were completely erad-
icated and inhibition of tumor angiogenesis and inﬁltra-
tion of T cells and macrophages were revealed.
IL-12
IL-12 is secreted by antigen-presenting cells such as
dendritic cells, macrophages or microglia [70]. Among
cytokines, it has been demonstrated that IL-12 possesses
particularly potent antitumor properties [71]. It is be-
cause IL-12 plays a critical role in mediating inﬂamma-
tory and immune responses in host defense, IL-12 exerts
a variety of biological eﬀects on T cells and natural killer
(NK) cells [72], including induction of interferon (IFN)-
γ production [71], enhancement of proliferation and cy-
tolytic function of T cells and NK cells [73], and promo-
tion of the Th1-type immune response [74]. In addition
to stimulatory eﬀects on the immune system, IL-12 is also
a potent antiangiogenic factor [75]. Local delivery of IL-
12 by genetically engineered cells signiﬁcantly prolongs
thesurvivaltimeinanimalswithbraintumor[47].More-
over, a single intratumoral treatment of nude mice with
a vaccinia virus (VV) expressing IL-12 induced signiﬁ-
cant tumor growth inhibition [48]. However, most ani-
mals injected with high doses of recombinant viruses (105
to 107 pfu) showed signs of cytokine toxicity.
Interferon(IFN)
IFNs are produced by activated immune cells includ-
ing T cells, NK cells, and monocyte lineage cells. Glioma
cells transfected with the human β-interferon gene by li-
posomes,elicitsystemicimmunereactionsandinhibitthe
tumor growth [49]. In addition, IFNs directly stimulate
cell diﬀerentiation and apoptosis via signals from inter-
feron receptors on glioma cells [50].28 Takao Kanzawa et al 2003:1 (2003)
TNF-α
Tumor necrosis factor (TNF)-α was initially supposed
to be a promising cancer therapeutic reagent. However,
recent investigation shows that TNF-α does not kill most
types of cancer cells partly due to the activation of an
anti-apoptotic gene, NF-κB[ 76]. Therefore, suppressing
NF-κBi se x p e c t e dt op o t e n t i a t eT N F - α-induced apop-
tosis. Recently, it has been demonstrated that combina-
tion of TNF-α with other cytokines [51], radiation [52],
chemotherapy [53], or hyperthermia [54]i sm o r ee ﬀec-
tive in therapy for glioma models than single treatments.
Others
Angiogenesisinhibitors
Based on the observation that gliomas are among the
most angiogenic tumors, therapeutic strategies aimed to
inhibit angiogenesis are theoretically attractive. Angio-
statin, an internal peptide fragment of plasminogen, has
recentlybeenshowntopotentlyinhibitendothelialprolif-
eration in vitro and tumor growth in vivo [77]. The AAV
(adeno-associated virus) vector has been able to deliver
sustained and high-level gene expression in vivo. Intratu-
moral [55] or intramuscular [56] injection of a high-titer
AAV-angiostatin vector has rendered eﬃcacious tumor
s u p p r e s s i o na n dr e s u l t e di nl o n g - t e r ms u r v i v a l .H o w e v e r ,
recombinant angiostatin, a peptide fragment, might be
unstable in vivo. A tricistronic retroviral vector, express-
ing natural antiangiogenic factors, inhibits angiogenesis
in vitro, but is not able to block tumor progression in vivo
[57]. A sustained in vivo protein delivery is required to
achieve the therapeutic eﬀects. Endostatin, internal pep-
tide fragment of 18 collagen, is also an angiogenic in-
hibitor. Engineered C6 cells that endogenously express
mouse endostatin reduced tumor growth in vivo [58].
However, complete tumor inhibition was not observed in
either the athymic or immunocompetent tumor models.
Antiangiogenetic therapy using these peptides might be
developed as an adjuvant gene therapy for the eﬀective
treatment of malignant gliomas.
Neuralstemcells
Gene therapy of glioblastomas is limited because vi-
ral vectors usually are unable to survive for long time,
continue to express proteins, and hardly reach glioblas-
toma cells inﬁltrating the brain parenchyma. Neural stem
cells, implanted distant from brain tumor lesion into ex-
perimental intracranial gliomas in vivo, migrated brain
parenchyma towards brain tumor site, chasing the inﬁl-
trating tumors [59]. This migratory cell delivery method
has the potential to expand the range of delivery of HSV-1
vectors to tumor cells in the brain [60]. Genetically engi-
neering neural stem cells expressing IL-4 elicited the sys-
temicimmuneresponseandinhibitedtumorgrowth[61].
Moreover, supernatant of neural stem cells inhibited the
proliferation of glioma cells [61]. Therefore, neural stem
Table 2. Vectors.
Viral vectors References
Retrovirus [8, 13, 15, 44, 57]
Adenovirus [5, 14]
Adeno-associated virus [9, 56]
Nonviral vectors References
Antisense oligonucleotide [25, 33, 34, 80, 81]
Naked DNA plasmid [32, 49, 82, 83]
cells may be an ideal vehicle to overcome the above diﬃ-
culties in gene therapy of malignant gliomas.
VECTORS
Vector development is an important ﬁeld of study, be-
cause eﬃcacy of gene transfer depends mostly on the abil-
ity of vectors to be incorporated into tumor cells. Vectors
for gene therapy can be divided into classes of viral and
nonviral systems (Table 2). Viruses are eﬀective vehicles
for gene delivery as they can enter human cells and ex-
press their genes speciﬁcally and eﬃciently. The main de-
vice for viral vector development is improving the target-
ing eﬃciency of viruses, while abrogating their ability to
cause disease. Modifying the viral genome to remove se-
quences necessary for viral replication and pathogenecity
makes it possible to achieve these goals. The removed vi-
ral coding sequence can be replaced with exogenous ther-
apeutic genes. Such genetically engineered viruses theo-
retically keep wild-type viral cellular tropism and ensure
transgene expression in the target cell population with-
out causing harmful diseases. Eﬀorts to alter the natural
tropism of viruses by manipulating the viral components
that mediate cell binding and internalization represent a
means of leading viruses speciﬁcally to chosen target cells.
Viralvectors
Retrovirus
Retrovirus and adenovirus have been used for a wide
variety of gene therapy applications. Retrovirus is a single
strand RNA virus. Retrovirus enters cells by binding sur-
face envelope protein, encoded by the env gene, to speciﬁc
cellularreceptors.Afterenteringcells,theviralenzymere-
verse transcriptase, encoded by the pol gene, transcribes
theviralgenomeintoadouble-strandDNAcopy.Double-
strand DNA can enter the nucleus of dividing cells and
become integrated randomly into the host genome. This
event occurs preferentially in dividing cells, meaning the
virus does not enter neurons or other normal brain cells.
Retroviruses used in gene therapy protocols are designed
to be replication-deﬁcient by removing their gag, pol,a n d
env genes. Therefore, infectious but replication-deﬁcient
retrovirus particles are produced in packaging cells that
express retrovirus gag, pol,a n denv genes from plasmids
lacking the packaging sequence. A great variety of in vivo2003:1 (2003) Current and Future Gene Therapy for Malignant Gliomas 29
experiments [13, 44, 57] and clinical trials [8, 15] using
retroviral vectors for gene therapy for malignant glioma
have been performed. There are some drawbacks to use
retrovirusesasvectors.Retroviruspackagingcellsproduce
relativelylowtiters.Theretrovirusgenomeissmall,which
limits the size of genetic constructs they can carry. Ran-
dom integration into the host genome may disrupt cellu-
lar genes by insertional mutagenesis.
Adenovirus
Adenovirusisadouble-strandDNAvirus.Adenovirus
enters cells by binding to the adenoviral receptor, which
promotes interaction of viral arginine-glycine-aspartate
sequences with cellular integrins. After internalization,
the virus escapes from cellular endosomes, partially disas-
sembles and translocates to the nucleus, where viral gene
expression begins. They can produce in high titers and
infect non-dividing cells. Gene expression occurs with-
out integration into the host genome and gutless ade-
novirus oﬀers the opportunity to develop vectors with
expanded capacity for therapeutic transgenes. Transduc-
tion eﬃciency of adenovirus is better than that of retro-
virus. One of the drawbacks is that the induced genomes
decrease by cell divisions. The administration is limited
only once, as it possesses high antigenicity. Sandmair et
al compared the eﬀect of HSV-tk gene therapy combined
with ganciclovir medication in malignant gliomas be-
tweenretrovirus-packagingcellandadenovirusgenether-
apy [14]. Although the results are from a small number
of patients and should be interpreted cautiously, adenovi-
ral HSV-tk gene therapy seems to be beneﬁcial as shown
by magnetic resonance imaging (MRI)-determined tu-
mor regrowth, 3 months after gene therapy, and the sur-
vival of patients [14].
Adeno-associatedvirus
Enhanced gene delivery has been demonstrated in
preclinical studies using adeno-associated viruses (AAV)
vectors targeting malignant glioma cells [9, 56]. AAV is a
native human parvovirus that does not cause any known
human disease. They enter cells after binding to heparan
sulfate but need coinfection with a helper virus (aden-
ovirus or herpes virus) to replicate. Without coinfection
of helper virus, AAV infection leads to latency, in which
the viral genome remains in an integrated form or as epi-
somal DNA. Subsequent infection of the cell with a virus
capableofprovidingthenecessaryhelperfunctionsallows
replication to proceed. AAV vectors have a number of po-
tential advantages over retroviral and adenoviral vectors.
They can infect a wide range of host cells independent
of their cell cycling status and are stably integrated and
maintained in the host genome in which transient trans-
gene expression may be adequate. The drawbacks of AAV
as vectors for gene therapy are limited packaging capac-
ity of approximately 5kbp and gene expression that may
be slow to reach its peak. In addition, production requires
helper viruses, which may contaminate preparations for
preclinical and clinical use.
Nonviralvectors
Gene transfer using nucleic acid therapeutics or non-
viral vectors is much less immunogenic and cytotoxic
than viral-vector systems. Although major weakness of
nonviral vectors is that transduction eﬃciency is signif-
icantly lower than viral vectors, it can be overcome by
frequent intratumoral injection or application of osmotic
minipumps or polymer/microsphere system as described
below.
Antisenseoligonucleotide
Over the last two decades, cloning and sequencing of
the critical genes in tumorigenecity have made progress
remarkably. Many target genes attractive for antisense
therapy have been identiﬁed. Antisense oligonucleotides
are designed to bind to a certain sequence of speciﬁc
mRNA and degrade it, providing a powerful tool for
the cancer therapy. We have recently selected telomerase,
a ribonucleoprotein enzyme, as a target for the ther-
apy of malignant gliomas [25, 33, 34]. Telomerase is
considered as a potential target of cancer therapy be-
cause malignant gliomas are predominantly telomerase-
positive, while normal brain tissues do not express the
enzyme [78, 79]. We have shown that a 19-mer antisense
oligonucleotide against human telomerase RNA linked to
a2
 ,5
 -oligoadenylate (2-5A) inhibited malignant tumors
growth in subcutaneous or brain tumor models in mice
[25, 33, 34]. Interestingly, inhibition of telomerase ac-
tivity resulted in apoptotic cell death. Angiogenic factors
are also potentially optimal targets for antisense oligonu-
cleotidebecausemalignantgliomasarehighlyangiogenic.
The antisense therapy against vascular endothelial growth
factor(VEGF)wasusefulindown-regulationofVEGFex-
pression, resulting in inhibition of growth of malignant
glioma cells in vivo [80, 81].
NakedDNAplasmid
Gene transfer with naked DNA plasmid in the pres-
ence of the modiﬁed liposomes such as cationic liposome
or the hemagglutinating virus of Japan (HVJ) liposome
has been developed and applied to the treatment of ma-
lignant tumors. Multiple intratumoral administrations of
liposomes containing the murine IFN-β gene resulted in
the reduction of tumors in the brains of mice and elicited
cytotoxic T lymphocytes without side eﬀects [49]. In-
tramuscular injection of DNA plasmid encoding murine
IFN-α leads to potent antitumor eﬀects in mice bearing
subcutaneousgliomacells[82].Moreover,thisgenetrans-
fer system has been applied to the treatment using the
suicidegene[83],apoptosis inducible-genes[32],because
this delivery system can be repeated.30 Takao Kanzawa et al 2003:1 (2003)
Neural stem cells producing malignant glioma-speciﬁc therapeutic product
Neural stem cells
Intratumoral injection
MIGRATION
Cell death
Malignant glioma cells
Figure 1. Prospective gene therapy for malignant gliomas.
Table 3. Delivery systems.
References
Direct intratumoral injection
[5, 8, 9, 13, 14, 15, 25, 32,
33, 34, 36, 37, 38, 39, 40,
44, 47, 49, 56, 57, 80, 81,
82]
Osmotic minipump [83]
Polymer/microsphere [84, 85, 86]
Neural stem cell [59, 60, 61]
DELIVERY SYSTEMS
Thetransferoftherapeuticgenesintomalignantbrain
tumors is the subject of experimental models and clinical
trialofgenetherapy(Table 3).Mostapproacheshaveused
direct intratumoral placement of a variety of vectors and
genes, such as retroviruses [8, 13, 15, 44, 57], replication-
defective adenoviruses [5, 14], replication-competent or-
conditioned oncolytic viruses [36, 37, 38, 39, 40], anti-
senseoligonucleotides[25,33,34,80,81],andnakedplas-
midvectors[32,49,82,83].Theseapproacheshaveshown
the eﬃciency of gene therapy. However, these approaches
need to repeatinjections or areunabletokeep continuous
gene expression.
Using a minipump combined with stereotaxic tech-
niques allows continuous delivery of therapeutic genetic
materials into the brain. Continuous intracerebral deliv-
ery of liposome-mediated HSV-tk gene complexes using
an osmotic minipump led to tumor regression in the
treated animal [83]. Polymer microspheres can encap-
sule antisense oligonucleotide, naked DNA plasmid, viral
particle, or monoclonal antibody, and release them. This
Table 4. Targeting.
References
HTERT [32, 87, 88]
MBP [30, 31]
EGFR [90, 91]
Stress (hyperthermia, hypoxia) [92, 93]
system not only decreases treatment frequency, but also
reduces the potent immune response by sequestering the
content from antibody exposure, leading to improvement
of in vivo eﬃcacy [84, 85, 86]. However, the above sys-
tems are unable to eﬀectively distribute the genetic ma-
terials into the target cell population. As described above
(Table 1),neuralstemcellsmayhavethepotentialtochase
the inﬁltrating tumor cells [59, 60, 61].
TARGETING
Gene transfer vectors will dramatically increase the
safety and eﬀectiveness of cancer gene therapy, if they can
restrict expression of the therapeutic products to the tar-
get tumors. Substances that are overexpressed in tumor
c e l l sb u tn o ti nn o r m a lc e l l sa r eg o o dt a r g e t sf o rg e n e
therapy (Table 4). Although no speciﬁc marker is known
for malignant gliomas, four targets including us came up
with expression regulating system using speciﬁc promot-
ers. First, we used the promoter of the human telom-
erase reverse transcriptase (hTERT) gene and developed
expression vectors of caspase-6 [32], caspase-8 [87], or
FADD [88] under the control of the promoter, respec-
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transcriptional level of the hTERT gene [89]. Since about
75% of malignant gliomas have telomerase activity while
normal brain tissues do not have the enzyme [78, 79], we
can restrict the expression of apoptosis-inducing proteins
to malignant glioma cells. We showed that the growth of
subcutaneous tumors was inhibited due to induction of
apoptosis after the treatment [32, 87, 88]. Second, Shi-
nouraetalusedthemyelinbasicprotein(MBP)promoter
to regulate the expression of Bax and caspase-8 [30, 31].
They showed that the growth of tumors in the animal
modelwassuppressed.Third,epidermalgrowthfactorre-
ceptor (EGFR) is often highly expressed in tumor but not
in normal brain. EGFR may be a good target to increase
the selectivity of delivering genes to tumor cells [90, 91].
Forth, stress can also be a target for tumor speciﬁc expres-
sion of therapeutic genes. The presence of hypoxic cells
in human brain tumor is an important factor leading to
resistance to radiation therapy. However, this physiologi-
cal diﬀerence between tumor and normal tissues also pro-
videsthepotentialfordesigningcancer-speciﬁcgenether-
apy [92]. When the gene expression is triggered by heat
stress, combined therapeutic eﬀects of hyperthermia and
gene therapy may be promising [93].
CONCLUSIONS
In recent years, many neuro-oncologists have focused
on evolving gene therapy as a new therapeutic modal-
ity for malignant gliomas. However, clinical success has
been limited due to insuﬃcient gene transfer or limited
spread of therapeutic genes. These obstacles may be over-
come by neural stem cell-guided gene therapy (Figure 1).
Neural stem cells are expected to migrate extensively into
malignant gliomas in the brain, although further inves-
tigation is necessary. Therefore, the application of neural
stem cells producing tumor-speciﬁc therapeutic product
will oﬀer a means of accessing invasive tumor cells. If we
can engineer neural stem cells to produce oncolytic virus
as tumor-speciﬁc therapeutic product, this approach may
be signiﬁcantly enhanced. It is expected that replication-
conditionalorcompetentoncolyticviruswillsigniﬁcantly
increase the extent of gene transfer into tumors com-
pared to replication-defective virus. However, issues such
as controlling virus replication and keeping normal cells
intact should be conﬁrmed. The use of tumor-speciﬁc
promoter such as hTERT promoter system in the brain
will increase the safety of oncolytic virus produced by
neural stem cells.
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